Bracco Diagnostics Inc. Introduces New CardioGen-82 Infusion System

46

Bracco Diagnostics Inc., the U.S subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, announced the FDA approval of its new CardioGen-82 infusion system to enhance automation, efficiency and simplicity in cardiac position emission tomography (PET) myocardial perfusion imaging (MPI). This next-generation infusion system model will replace the company’s current infusion system.

Vittorio Puppo, President and CEO of Bracco Diagnostics Inc. said, “The new infusion system exemplifies Bracco’s significant investment in the cardiac PET imaging modality and isthe culmination of thoughtful design and feedback from healthcare providers. Developing innovative products that support clinicians in diagnosing coronary artery disease is our commitment to the patients we serve.”

Designed for efficiency, flexibility, and ease of use

Developed with clinicians and nuclear medicine technologists in mind, the new infusion system is elegantly designed with intuitive and ergonomic details that provide easy access to all system components while minimizing radiation exposure for staff and patients.

Other smart features enable work flow efficiencies that can save nearly an hour at the beginning of each day of patient imaging and eliminate manual record keeping. A choice of dosing options and other protocol parameters make changes in scheduling and patient needs easy to accommodate.

Bracco’s commitment to excellence in cardiac PET imaging
“Cardiac PET MPI with the CardioGen-82 generator has helped accurately diagnose thousands of patients since 1989,” said Kim McDaniel, Senior Director, Nuclear Medicine Sales and Market Support. “Bracco was the first company to heavily invest in the modality for the diagnosis of coronary artery disease,and our introduction of the new infusion system is one more example of our commitment to our customers and patients worldwide.”

About Bracco Imaging S.p.A.Bracco Imaging S.p.A., part of the Bracco Group, is a world-leading diagnostic imaging provider, headquartered in Milan, Italy.Bracco Imaging offers a product and solution portfolio for all key diagnostic imaging modalities: X-ray imaging (including Computed Tomography-CT, Interventional Radiology, and Cardiac Catheterization), magnetic resonance imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers and novel PET imaging agents. Our continually evolving portfolio is completed by a range of medical devices, advanced administration systems and dose-management software. The Company operates in over 100 markets worldwide, either directly or indirectly, through subsidiaries, joint ventures, licenses and distribution partnership agreements. Bracco Imaging has a strong presence in key geographies: North America, China, Europe, Japan, Brazil, Mexico and South Korea.